These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11890240)

  • 1. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy.
    May F; Hartung R; Breul J
    BJU Int; 2001 Nov; 88(7):702-7. PubMed ID: 11890240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
    Steuber T; Erbersdobler A; Graefen M; Haese A; Huland H; Karakiewicz PI
    Cancer; 2006 Feb; 106(4):775-82. PubMed ID: 16400637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
    Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
    BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
    Antunes HP; Parada B; Carvalho J; Eliseu M; Jarimba R; Oliveira R; Tavares-da-Silva E; Figueiredo A
    Arch Ital Urol Androl; 2018 Sep; 90(3):191-194. PubMed ID: 30362685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ; Partin AW; Epstein JI; Walsh PC
    Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases a Montsouris Institute.
    Guillonneau B; el-Fettouh H; Baumert H; Cathelineau X; Doublet JD; Fromont G; Vallancien G
    J Urol; 2003 Apr; 169(4):1261-6. PubMed ID: 12629339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy.
    Lowe BA; Lieberman SF
    J Urol; 1997 Oct; 158(4):1452-6. PubMed ID: 9302141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer.
    Dash A; Sanda MG; Yu M; Taylor JM; Fecko A; Rubin MA
    Urology; 2002 Aug; 60(2):276-80. PubMed ID: 12137826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Positive Surgical Margins after Radical Prostatectomy on Disease Progression and Adjuvant Treatment in Pathologically Localized Prostate Cancer.
    Tomasković I; Milicić V; Tomić M; Ruzić B; Ulamec M
    Coll Antropol; 2015 Sep; 39(3):697-700. PubMed ID: 26898068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Perioperative parameters and prognosis analysis of patients aged 80 years or older treated with radical prostatectomy for prostate cancer].
    Zhang F; Zhang SD; Xiao CL; Huang Y; Ma LL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 50(5):822-827. PubMed ID: 30337742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
    Han M; Walsh PC; Partin AW; Rodriguez R
    J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of the pT2 substage classification in prostate adenocarcinoma.
    Ettel M; Kong M; Lee P; Zhou M; Melamed J; Deng FM
    Hum Pathol; 2016 Oct; 56():57-63. PubMed ID: 27251951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.